Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease

2016546 citationsJournal Articlegreen Open Access

Authors

Nicolaus Kröger · Universität Hamburg

Carlos Solano · Hospital Clínico Universitario de Valencia

Christine Wolschke · University Medical Center Hamburg-Eppendorf

Giuseppe Bandini · University of Bologna

Francesca Patriarca · University of Udine

Massimo Pini · Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo

Arnon Nagler

Abstract

The inclusion of ATG resulted in a significantly lower rate of chronic GVHD after allogeneic transplantation than the rate without ATG. The survival rate was similar in the two groups, but the rate of a composite end point of chronic GVHD-free survival and relapse-free survival was higher with ATG. (Funded by the Neovii Biotech and the European Society for Blood and Marrow Transplantation; ClinicalTrials.gov number, NCT00678275.).

Topics & Keywords

Hematopoietic Stem Cell Transplantation T-cell and B-cell Immunology Immune Cell Function and Interaction

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 374, Issue 1, pp. 43-53

DOI: 10.1056/nejmoa1506002

Field-Weighted Citation Impact: 48.46